<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01586208</url>
  </required_header>
  <id_info>
    <org_study_id>NEU-2009-01</org_study_id>
    <nct_id>NCT01586208</nct_id>
  </id_info>
  <brief_title>Refractory Status Epilepticus Treatment Study</brief_title>
  <official_title>Refractory Status Epilepticus: Plasmatic Levels Monitorization Utility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Vall d'Hebron</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Identify the most effective dose of valproic acid when used in combination with phenytoin for
      treatment of patients with refractory status epilepticus, which allow a better clinical
      course and prognosis of the disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase III Clinical trial, to identify the most effective dose of valproic acid (20mg/kg
      bolus, 1mg/kg/h maintenance vs 40mg/kg bolus, 2mg/kg/h maintenance) in combination with
      phenytoin, in patients with refractory status epilepticus.

      Multicenter clinical trial, single-blind, prospective, randomized 1:1 assignment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>status epilepticus resolution</measure>
    <time_frame>after 48h treatment administration</time_frame>
    <description>After 48h treatment administration the status epilepticus has to be solved without any other antiepileptic medications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimation of pharmacokinetic parameters of valproate (VPA) and phenytoin (PHT)</measure>
    <time_frame>During 48h post valproate administration</time_frame>
    <description>Estimation of pharmacokinetic parameters of VPA (Cl: clearance, Vd: volume of distribution) and PHT (Vmax: maximum speed of metabolism and Km: plasma concentration at which the rate of metabolism is half the maximum)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Grand Mal Status Epilepticus</condition>
  <condition>Non-convulsive Status Epilepticus</condition>
  <arm_group>
    <arm_group_label>40mg/kg intial valproate bolus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient receives a 40mg/kg valproate bolus with a maintenance of 1mg/kg/h, after benzodiazepine + phenytoin administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20mg/Kg intial bolus valproate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient receives a 20mg/kg valproate bolus with a maintenance of 1mg/kg/h, after benzodiazepine + phenytoin administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valproic acid (VPA)</intervention_name>
    <description>Best dosage at the initial bolus of VPA in patient with satatus epilepticus refractarius (after benzodiazepine + phenytoin treatment)</description>
    <arm_group_label>40mg/kg intial valproate bolus</arm_group_label>
    <arm_group_label>20mg/Kg intial bolus valproate</arm_group_label>
    <other_name>Valrpoic acid</other_name>
    <other_name>Phenytoin</other_name>
    <other_name>Benzodiazepines</other_name>
    <other_name>Status Epilepticus Refractarius</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients ≥ 18 years of age who meet the diagnosis of EER seizure, and previously they
             have been treated according to the clinical protocol at our center status (Diazepam
             10mg Clonazepam 1mg and Phenytoin or iv at a dose of 20mg/kg in case persistence of
             the clinic):

             -Present seizures for at least 30 minutes without regaining awareness among them.

          2. Patients ≥ 18 years of age who meet the diagnosis of nonconvulsive EER, and previously
             they have been treated according to the clinical protocol at our center status
             (Diazepam 10mg Clonazepam 1mg and Phenytoin or iv at a dose of 20mg/kg in case
             persistence of the clinic):

               -  After submitting an EER seizures that yield clinically performed an EEG that
                  shows SE electricity.

               -  Evidence of a non-convulsive SE to perform an EEG of a patient admitted for any
                  cause, either by filing seizures, altered mental status, or any other cause, and
                  to persist after the treatment administered previously discussed.

          3. Patients in whom it has obtained the written informed consent by the representative
             and/or patient, as the case

        Exclusion Criteria:

          1. Patients with severe cerebral anoxia, when the first EEG evidences a pattern of
             flare-suppression.

          2. Patients who registers PLEDs (periodic epileptic lateralaized Discharges) without
             clinical seizure activity association to register or without electrical crises.

          3. Patients &lt; 18 years of age.

          4. Patients in whom there is diagnostic doubt (eg non-convulsive status among and
             encephalopathy).

          5. Pregnant or breastfeeding.

          6. Patients with allergy to phenytoin, hydantoin or hypersensitivity to sodium valproate

          7. Patients with porphyria

          8. Patients with severe liver disease or dysfunction.

          9. Patients with heart block or second and third grade sinus bradycardia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mercè Falip, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2012</study_first_submitted>
  <study_first_submitted_qc>April 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2012</study_first_posted>
  <last_update_submitted>March 10, 2013</last_update_submitted>
  <last_update_submitted_qc>March 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Mercè Falip</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>refractory status epilepticus</keyword>
  <keyword>valproic acid</keyword>
  <keyword>phenytoin</keyword>
  <keyword>benzodiazepines</keyword>
  <keyword>Valproic acid initial dosage in status treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Status Epilepticus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
    <mesh_term>Phenytoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

